Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases.
We report two patients who developed an inflammatory bowel disease (IBD) shortly after beginning combined alpha-interferon and ribavirin treatment for HCV-related chronic hepatitis. The previous clinical history was negative for IBD in both patients, who developed diarrhoea and rectal bleeding 10 days and 6 months, respectively, after the initiation of therapy. The history, therapeutic management and the possible causal relationships of these cases are discussed.
Villa
Federica
F
Department of Gastroenterology, IRCCS Policlinico Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, Italy.
Rumi
Maria Grazia
MG
Signorelli
Clementina
C
Saibeni
Simone
S
Del Ninno
Ersilio
E
Ferrero Bogetto
Stefano
S
de Franchis
Roberto
R
Vecchi
Maurizio
M
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced*; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin